Login / Signup

A Randomized Controlled Trial of Dapagliflozin Plus Once-Weekly Exenatide Versus Placebo in Individuals with Obesity and Without Diabetes: Metabolic Effects and Markers Associated with Bodyweight Loss.

Maria J PereiraPer LundkvistPrasad G KambleJoey LauJulian G MartinsC David SjöströmVolker SchneckeAnna WalentinssonEva JohnssonJan W Eriksson
Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2018)
AstraZeneca.
Keyphrases
  • type diabetes
  • insulin resistance
  • metabolic syndrome
  • cardiovascular disease
  • weight loss
  • glycemic control
  • weight gain
  • high fat diet induced
  • randomized controlled trial
  • double blind
  • clinical trial
  • phase iii